Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Int J Pharm. 2011 Jan 26;408(1-2):163–172. doi: 10.1016/j.ijpharm.2011.01.044

Table 6.

Maximum tolerated dose (MTD, mg/kg) following intravenous injection of liposomal AmB formulations prepared from DSHemsPC in BALB/c mice

AmB Formulation No. of animals Maximum tolerated dose (mg/kg)
F4-DSHemsPC/DSPC/DSPG/AmB 3 12.5
F8-DSHemsPC/DPPC/DPPG/AmB 1 2.5
F11-DSHemsPC/DMPC/DMPG/AmB 3 10
F12-DSHemsPC/DMPC/DMPG/AmB 3 5
F15-DSHemsPC/HSPC/DSPG/AmB 1 2.5
F16-DSHemsPC/HSPC/DSPG/AmB 1 2.5
F19-DSHemsPC/HSPC/DSPG/AmB 3 20
F20-DSHemsPC/HSPC/DSPG/AmB 1 2.5

F21-DSHemsPC/DSPC/DSPG/AmB 1 5
F22-DSHemsPC/DPPC/DPPG/AmB 1 <2.5
F23-DSHemsPC/DMPC/DMPG/AmB 3 20
F24-DSHemsPC/DMPC/DMPG/AmB 1 5
F25-DSHemsPC/HSPC/DSPG/AmB 1 5
F26-DSHemsPC/HSPC/DSPG/AmB 1 5
F27-DSHemsPC/DSPC/DSPG/AmB 3 10
F28-DSHemsPC/DPPC/DPPG/AmB 1 5
F29-DSHemsPC/DMPC/DMPG/AmB 4 60
F30-DSHemsPC/DMPC/DMPG/AmB 3 10
F31-DSHemsPC/HSPC/DSPG/AmB 3 10
F32-DSHemsPC/HSPC/DSPG/AmB 1 7.5
AmBisome™ 2 >140
Fungizone™ 1 2